Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study

Angelika Chachaj; Jerzy Wiśniewski; Justyna Rybka; Aleksandra Butrym; Monika Biedroń; Małgorzata Krzystek-Korpacka; Mariusz Grzegorz Fleszar; Maciej Karczewski; Tomasz Wróbel; Grzegorz Mazur; Andrzej Gamian; Andrzej Szuba

doi:10.1371/journal.pone.0197148

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study

PLoS One. 2018 May 22;13(5):e0197148. doi: 10.1371/journal.pone.0197148. eCollection 2018.

Affiliations

¹ Department of Angiology, Wroclaw Medical University, Wroclaw, Poland.
² Department of Biochemistry, Wroclaw Medical University, Wroclaw, Poland.
³ Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
⁴ Department of Physiology, Wroclaw Medical University, Wroclaw, Poland.
⁵ Department of Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
⁶ Department of Mathematics, The Faculty Of Environmental Engineering And Geodesy, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.
⁷ Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

Abstract

The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Arginine / analogs & derivatives*
Arginine / blood
Biomarkers, Tumor / blood*
Case-Control Studies
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / blood
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Leukemia, Myeloid, Acute / blood
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / mortality*
Lymphoma, Non-Hodgkin / blood
Lymphoma, Non-Hodgkin / diagnosis
Lymphoma, Non-Hodgkin / mortality*
Male
Middle Aged
Prognosis
Prospective Studies
Survival Rate
Young Adult

Substances

Biomarkers, Tumor
symmetric dimethylarginine
N,N-dimethylarginine
Arginine

Grants and funding

The study was supported by Wroclaw Medical University, Grant number 18/Pbmn. The funding body accepted the study protocol and had no later influence on study performance, collection, analysis and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication.